KINETICS AND BIODISTRIBUTION IN RELATION TO TUMOR-DETECTION WITH IN-111 LABELED OV-TL 3 F(AB')2 IN PATIENTS WITH OVARIAN-CANCER

被引：10

作者：

MASSUGER, LFAG ^{[1
]}

CLAESSENS, RAMJ ^{[1
]}

KENEMANS, P ^{[1
]}

VERHEIJEN, RHM ^{[1
]}

BOERMAN, OC ^{[1
]}

MEEUWIS, APW ^{[1
]}

SCHIJF, CPT ^{[1
]}

BUIJS, WCAM ^{[1
]}

HANSELAAR, TGJM ^{[1
]}

CORSTENS, FHM ^{[1
]}

机构：

[1] UNIV HOSP NIJMEGEN,DEPT NUCL MED,6500 HB NIJMEGEN,NETHERLANDS

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1991年 / 12卷 / 07期

关键词：

D O I：

10.1097/00006231-199107000-00004

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The biological behaviour of In-111-labelled OV-TL 3 F(ab')2 was studied in 22 patients with suspected ovarian cancer. After i.v. injection with 140 MBq In-111-OV-TL 3 F(ab')2 (1 mg) blood samples were taken up to 96 h and urine and faeces were collected throughout the whole study. At surgery, 5 to 7 days post-injection, primary and metastatic tumour tissues, as well as fragments of several normal tissues, were removed and In-111 uptake was measured. Blood activity disappeared with half-life values of 6.1 +/- 1.1 and 17.9 +/- 6.5 h. Within 96 h excretion in urine and faeces was 16.1 +/- 2.0% i.d. (mean +/- S.D.) and 3.1 +/- 1.9% i.d., respectively. Mean tissue uptake, expressed as % i.d. kg-1 was 3.9 +/- 1.0 for primary tumour, 11.5 +/- 5.0 for liver and 0.4 +/- 0.1 for several normal background tissues. Higher tumour uptake correlated with a higher detection rate at immunoscintigraphy. However, no strict correlation was found between the amount of tumour uptake and the expression of the monoclonal antibody defined OA3 antigen. Quantitation of organ activity, using region of interest analysis, resulted in mean peak organ activities for the liver of 16% i.d., spleen 9% i.d. and kidney 4% i.d. Distribution data indicate that besides specific antibody-antigen interaction several other mechanisms play a role in uptake in tumour and other tissues.

引用

页码：593 / 609

页数：17

共 29 条

[1]

Epenetos A.A., Mather S., Granowska M., Et al., Targeting of iodine-123-labelled tumour associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours, Lancet, 2, (1982)

[2]

Verheijen R., Massuger L., Kenemans P., Haisma H.J., Epenetos A.A., Polymorphic epithelial mucin and CA125-bearing glycoprotein as targets for imaging and therapy with monoclonal antibodies, Cancer Rev, 145, pp. 11-12, (1988)

[3]

Fairweather D.S., Bradwell A.R., Dykes P.W., Vaughan A.T., Watson-James S.F., Chandler S., Improved tumour localisation using indium-ill-labelled antibodies, Brmed J, 287, (1983)

[4]

Carrasquillo J.A., Mulshine J.L., Bunn B.A., Et al., Tumor imaging of In-111 T101 monoclonal antibody is superior to iodine-131 T101 in cutaneous T-cell lymphoma, J Nucl Med, 29, (1987)

[5]

Hnatowich D.J., Griffin T.W., Kosciuczyk C., Et al., Pharmacokinetics of an indium-111 labeled monoclonal antibody in cancer patients, J Nucl Med, 26, (1985)

[6]

Beatty J.D., Duda R.B., Williams L.E., Et al., Preoperative imaging of colorectal carcinoma with<sup>111</sup>In-labeled anticarcinoembryonic antigen monoclonal antibody, Cancer Res, 46, (1986)

[7]

Kalofonos H.P., Sivolapenko G.B., Courtnay-Luck N.S., Et al., Antibody guided targeting of nonsmall cell lung cancer using mIn-labeled HMFG1 F(Ab')2 fragments, Cancer Res, 48, (1988)

[8]

Poels L.G., Peters D., Van Megen Y., Et al., Monoclonal antibody against human ovarian tumor- associated antigens, J Natl Cancer Inst, 76, (1986)

[9]

Kiihnel R., Rao B.R., Poels L., Delemarre J., Kenemans P., Stolk J.G., Multiple parameter analyses of human ovarian cancer: Morphology, immunohistochemistry, steroid hormone receptors and aromatase, Anticancer Res, 8, (1988)

[10]

Henzen-Logmans S.C., Schipper N.W., Poels L.G., Kenemans P., Meyer C., Use of statistical evaluation of antigen profiles in differential diagnosis between colonic and ovarian adenocarcinomas, J Clin Pathol, 41, (1988)

← 1 2 3 →